HomeCompareGMDA vs RYLD

GMDA vs RYLD: Dividend Comparison 2026

GMDA yields 6116.21% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMDA wins by $442825559222013.75M in total portfolio value
10 years
GMDA
GMDA
● Live price
6116.21%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$442825559222013.81M
Annual income
$429,026,802,483,037,700,000.00
Full GMDA calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — GMDA vs RYLD

📍 GMDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMDARYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMDA + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GMDA pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMDA
Annual income on $10K today (after 15% tax)
$519,877.68/yr
After 10yr DRIP, annual income (after tax)
$364,672,782,110,582,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, GMDA beats the other by $364,672,782,110,582,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMDA + RYLD for your $10,000?

GMDA: 50%RYLD: 50%
100% RYLD50/50100% GMDA
Portfolio after 10yr
$221412779611006.94M
Annual income
$214,513,401,241,518,830,000.00/yr
Blended yield
96.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GMDA right now

GMDA
Analyst Ratings
7
Buy
1
Hold
Consensus: Buy
Altman Z
-12.9
Piotroski
2/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMDA buys
0
RYLD buys
0
No recent congressional trades found for GMDA or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMDARYLD
Forward yield6116.21%12.39%
Annual dividend / share$2.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$442825559222013.81M$45.3K
Annual income after 10y$429,026,802,483,037,700,000.00$2,682.98
Total dividends collected$441897573176239.63M$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GMDA vs RYLD ($10,000, DRIP)

YearGMDA PortfolioGMDA Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$622,321$611,620.80$11,939$1,239.34+$610.4KGMDA
2$36,238,251$35,572,368.18$14,158$1,382.89+$36.22MGMDA
3$1,974,670,479$1,935,895,550.07$16,682$1,532.59+$1974.65MGMDA
4$100,701,235,006$98,588,337,593.13$19,537$1,687.64+$100701.22MGMDA
5$4,806,495,889,234$4,698,745,567,778.20$22,752$1,847.20+$4806495.87MGMDA
6$214,743,265,021,614$209,600,314,420,132.84$26,355$2,010.43+$214743265.00MGMDA
7$8,981,610,447,341,976$8,751,835,153,768,850.00$30,376$2,176.45+$8981610447.31MGMDA
8$351,707,912,645,944,000$342,097,589,467,288,100.00$34,847$2,344.43+$351707912645.91MGMDA
9$12,896,034,335,491,684,000$12,519,706,868,960,524,000.00$39,800$2,513.54+$12896034335491.64MGMDA
10$442,825,559,222,013,800,000$429,026,802,483,037,700,000.00$45,269$2,682.98+$442825559222013.75MGMDA

GMDA vs RYLD: Complete Analysis 2026

GMDAStock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Full GMDA Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this GMDA vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMDA vs SCHDGMDA vs JEPIGMDA vs OGMDA vs KOGMDA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.